Provided by Tiger Trade Technology Pte. Ltd.

WAVE Life Sciences

13.41
+0.24501.86%
Volume:1.10M
Turnover:14.59M
Market Cap:2.49B
PE:-18.03
High:13.58
Open:13.07
Low:12.88
Close:13.16
52wk High:21.73
52wk Low:5.28
Shares:186.00M
Float Shares:157.87M
Volume Ratio:0.49
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7436
EPS(LYR):-0.7015
ROE:-86.51%
ROA:-28.33%
PB:20.02
PE(LYR):-19.11

Loading ...

Wave Life Sciences Ltd. Schedules Webcast to Review Fourth-Quarter and Full-Year Financial Results

Reuters
·
Feb 19

Latest Ratings from Top Wall Street Analysts: Microsoft Downgraded, Snap Upgraded

Deep News
·
Feb 06

Wave Life Sciences Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Feb 05

Wave Life Sciences initiated with a Buy at BofA

TIPRANKS
·
Feb 05

Analysts Have Conflicting Sentiments on These Healthcare Companies: Wave Life Sciences (WVE) and Eli Lilly & Co (LLY)

TIPRANKS
·
Feb 05

Wave Life Sciences Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Feb 03

Wave Life Sciences Ltd : Canaccord Genuity Raises Target Price to $43 From $40

THOMSON REUTERS
·
Feb 03

BUZZ-U.S. STOCKS ON THE MOVE-Abacus Global, McDonald's, Wave Life

Reuters
·
Feb 03

Wave Life Sciences: Regained WVE-006 Ownership and Platform Validation Support Buy Rating and $33 Target

TIPRANKS
·
Feb 03

BUZZ-Wave Life rises after regaining full rights to genetic disorder therapy from GSK

Reuters
·
Feb 03

Wave Life Sciences price target raised to $50 from $47 at Clear Street

TIPRANKS
·
Feb 03

BRIEF-Wave Life Sciences Plans To Accelerate Regulatory Engagement With Full Control Of WVE-006

Reuters
·
Feb 02

Wave Life Sciences Regains WVE-006 Rights, Plans Accelerated Path

TIPRANKS
·
Feb 02

Wave Life Sciences Ltd - Data From 400 Mg Cohort on Track for Q1 2026

THOMSON REUTERS
·
Feb 02

Wave Life Sciences Ltd - Expects Cash Runway Into Third Quarter of 2028

THOMSON REUTERS
·
Feb 02

Wave Life Sciences Ltd: Plans to Engage FDA on Potential Accelerated Approval Pathway for Wve-006, With Regulatory Feedback Anticipated Mid-2026

THOMSON REUTERS
·
Feb 02

Wave Life Sciences and GSK Advance Oligonucleotide Therapeutics Collaboration

Reuters
·
Feb 02

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

GlobeNewswire
·
Feb 02

Wave Life Sciences Ltd : Leerink Partners Raises Target Price to $35 From $28

THOMSON REUTERS
·
Jan 27

Wave Life Sciences Reports $602 Million Year-End Cash Position and Outlines 2026 Strategic Priorities

Reuters
·
Jan 13